Programme

EYENOVATE & RETINA FUTURA

CLINICAL TRIALS 2026

Preliminary Agenda – SUBJECT TO UPDATES – October 23, 2026

Thursday, 3 December 2026

07:30 – 08:30
Registration and welcome coffee
08:30 – 08:45

OPENING SESSION

Greetings and introduction: Stanislao Rizzo (Italy) · Francesco Faraldi (Italy) · Ram Palanki (EYENOVATE founding advisor)
08:45 – 09:35

SESSION 1 – OPHTHALMOLOGY INVESTMENT OUTLOOK PART I – BIG PICTURE

Moderator: Ram Palanki
Length
Speaker
Talk
Note
5'
Cameron Taylor
Bank of America
Public markets pulse: capital, sentiment & the ophthalmology outlook
 
5'
Firas Rahal
Exsight Ventures
2026: Review of the year of the Readouts
 
5'
Len Feiner
Bain Capital
The investor view: US market trends, capital flows & ophthalmology
 
5'
Paola Pozzi
Sofinnova Partners
The state of European Biotech: An investors’ perspective
 
5'
Larissa Bergin
Jones Day
Antitrust Risk as Investment Risk: Assessing Pharma M&A and competitive exposure
 
5'
Pierluigi Bruschetta
LSC Consultants
From Science to Market: The Changing Business of Retina
 
5'
Houman Hemmati
Optigo Biotherapeutics
Navigating a changing FDA: what ophthalmology innovators need to know
 
DISCUSSION (15')
09:35 – 10:50

SESSION 2 – THE HUNT FOR A DURABLE wAMD TREATMENT

Length
Speaker
Talk
Note
Data first: clinical trial results and scientific innovation
Moderators: Baruch Kuppermann (USA), Kourous Rezaei (USA)
5'
Baruch Kuppermann
USA
Extended Drug Delivery for the Treatment of Neovascular Age Related Macular Degeneration
 
5'
Anat Loewenstein
Israel
LUCIA Pivotal Phase 3 Trial Results: Primary Efficacy and Safety of Bioerodible EYP-1901 (vorolanib intravitreal insert) in Wet AMD
 
5'
Zofia Anna Nawrocka
Poland
Two-Year Evaluation of Intravitreal 4D-150 in a Phase-3 Comparable Wet AMD Cohort: Results from the Phase 2 PRISM Clinical Trial
 
5'
Dante Pieramici
USA
Subretinal Gene Therapy: Sura-vec – Status of the Largest Investigational Gene Therapy Program
 
5'
Darius Moshfeghi
USA
OTX-TKI – A Game Changer in the Real World
 
5'
Charles Wykoff
USA
Tabirafusp tedromer for wAMD: Efficacy and Safety Outcomes of the DAYBREAK Phase 3 Pivotal Study in nAMD
 
10'
Discussion
 
 
The companies' perspective
Moderator: Len Feiner (Bain Capital)
4'
Sherri Alexander
Regenxbio
Title tbd
 
4'
Bob Jahr
Outlook Therapeutics
Title tbd
 
4'
Michael J. O’Rourke
Re-Vana Therapeutics
Title tbd
 
PANEL DISCUSSION – The near and far future of wet AMD treatment: durability, new treatment pathways, combined therapies (15')

Panelists: Sherri Alexander (Regenxbio) · Bob Jahr (Outlook Therapeutics) · Namrata Saroj, OD (Ocular Therapeutix) · Dhaval Desai (4DMT) · Ramiro Ribeiro (EyePoint) · Bob Avery (USA) · Renato Bernardini (Italy) Annabel Samimy (Stifel) · Lili Nsongo (Leerink)

10:50 – 11:15
Coffee break
11:15 – 12:15

SESSION 3 – VASCULAR/DIABETIC RETINAL DISEASES: NEW ASSOCIATIONS AND TREATMENTS

Length
Speaker
Talk
Note
Data first: clinical trial results and scientific innovation
Moderators: Carl Awh (USA), Diana Do (USA)
5'
Diana Do
USA
Edonentan intravitreal implant, bringing disease-modifying potential to Glaucoma and Diabetic Retinopathy
 
5'
Charles Wykoff
USA
OLN324 Next-Generation Anti-VEGF/Ang-2: PoC Results & Rationale for Phase 3 Study Designs
 
5'
Lejla Vajzovic
USA
Suprachoroidal Delivery of Sura-vec: 3-year data for the ALTITUDE Study for NPDR
 
5'
Donald J. D’Amico
USA
Restoret (MK-3000) as Potential Therapeutic Agent for Retinal Vascular Disease
 
5'
Michael Singer
USA
Subcutaneous Migaldendranib for the Treatment of DME and nAMD: A Novel, Next Generation Nanomedicine
 
5'
Quan Dong Nguyen
USA
Brepocitinib in Noninfectious Uveitis: Results from the Phase 3 CLARITY Trials
 
10'
Discussion
 
 
The companies' perspective
Moderator: Annabel Samimy (Stifel)
4'
Peter Kaiser
Ocular Therapeutix
TKIs – Why This Has Us Excited
 
4'
Anders Haegerstrand
Annexin
Vanexin in RVO and DR-reperfusing retina
 
4'
Ramiro Ribeiro
EyePoint
Significance of IL-6 inhibition in DME and update on Phase 3 COMO/CAPRI Trials
 
4'
Stevan Segalen
Intalight
When Wider isn’t Better by Itself. Beyond Coverage: Precision and Versatility in Modern Retinal Imaging
 
PANEL DISCUSSION – From Controlling Neovascularization to Restoring Vascular Function (13')
Panelists: Peter Kaiser (Ocular Therapeutix) · Ramiro Ribeiro (EyePoint) · Doug Faunce (AbbVie) · Varun Malhotra (Ollin) · Paulo Stanga (UK)
12:15 – 13:05

SESSION 4 – THE FUTURE OF VISION: HOW INDUSTRY LEADERS ARE SHAPING THE FUTURE OF OPHTHALMIC INNOVATION (LARGE CAP PHARMA, BIOTECH, SURGICAL & IMAGING)

Moderators: Cameron Taylor (Bank of America), Annabel Samimy (Stifel), Daniel Ting (USA)
Length
Speaker
Talk
Note
4'
Doug Faunce
AbbVie
Title tbd
 
4'
Sergio Leal
Bayer
Bayer vision in Ophthalmology: from trusted partnerships to future innovation
 
4'
Lionel Jouet
Bausch + Lomb

Title tbd

 
4'
TBD
Eli Lilly
Title tbd
 
4'
Patrick Bussfeld
Boehringer Ingelheim
Advancing Ophthalmology Beyond Anti-VEGF
 
4'
Sean Madden
Alcon
UNITY® Surgical Platform – From Vision to Impact in Clinical Practice
 
4'
Bing Li
Intalight
Intalight, Light every sight. From DREAM to worldwide vision: Transforming Ophthalmology Through Light Driven Innovation
 
PANEL DISCUSSION (14')
Panelists: All + Nida Sen (Regeneron), Sascha Fauser (Roche), Sumie Takahara (MSD)
13:05 – 13:45

SESSION 5 – THE STREET'S VIEW: CAPITAL, CONVICTION, AND THE FUTURE OF OPHTHALMOLOGY

Length
Speaker
Talk
Note
PANEL DISCUSSION
Moderator: Emmett Cunningham (USA)
Panelists: Annabel Samimy (Stifel) · Len Feiner (Bain Capital) · Paola Pozzi (Sofinnova Partners) · Firas Rahal (Exsight Ventures) · Lili Nsongo (Leerink) · Cameron Taylor (Bank of America)
13:45 – 14:45
Lunch
14:45 – 16:15

SESSION 6 – INHERITED RETINAL DISEASES: SINGLE GENE, GENE AGNOSTIC, CELL THERAPY OR ORAL. THE WAYS TO EMERGE FROM INEVITABLE BLINDNESS

Length
Speaker
Talk
Note
Data first: clinical trial results and scientific innovation
Moderators: Bart Leroy (USA), Philip Ferrone (USA)
5'
Francesca Simonelli
Italy
Clinical updates on the ongoing LUCE Phase I/II Trial: a first dual AAV MYO7A gene therapy for retinitis pigmentosa associated with Usher Syndrome type 1B
 
5'
Sally Tucker
USA
Title tbd
 
5'
Aleksandra Rachitskaya
USA
Subretinal Gene Therapy Laru-Zova For X-Linked Retinitis Pigmentosa (XLRP): VISTA Clinical Trial Results
 
5'
Aaron Nagiel
USA
CLARICO, Phase I/IIa study of OpCT-001 in patients with primary photoreceptor disease
 
10'
Discussion
 
 
The companies' perspective
Moderator: Paola Pozzi (Sofinnova Partners)
4'
Natalia Misciattelli
AAVantgarde Bio
Transforming the lives of IRD patients by delivering therapies for Stargardt and Usher 1B
 
4'
Ben Yerxa
Opus Genetics
Title tbd
 
4'
Lance Baldo
Beacon Therapeutics
Transforming Vision, Transforming Lives – Pioneering Ocular Gene Therapy
 
4'
Michel Dahan
Alkeus
Title tbd
 
4'
Amit Rakhit
Bluerock
Delivering on the promise of cell therapy
 
4'
Hendrik Scholl
Belite Bio
Title tbd
 
4'
Alessandro Iannaccone
Astellas
Next-Generation RPE Cell Therapies: Leveraging Universal Cell Technology as An Approach to Macular Dystrophies
 
PANEL DISCUSSION – Inherited Retinal Diseases: Where Science, Strategy and investment converge (27')
Keynote Lecture by Jane Moseley (EMA): IRDs from a regulatory perspective (10′)

Panelists: Robert Giovanni Nisticò (AIFA), Natalia Misciattelli (AAVantgarde Bio) · Ben Yerxa (Opus Genetics) · Lance Baldo (Beacon Therapeutics) · Michel Dahan (Alkeus) · Amit Rakhit (Bluerock) · Peter Francis (Ray Therapeutics) · Hendrik Scholl (Belite Bio) · Paul Allen (Nanoscope), Francesca Simonelli (Italy)

16:15 – 17:15

SESSION 7 – THE FUTURE OF DRY AMD IN EUROPE

Length
Speaker
Talk
Note
Moderators: Fabio Baschiera (Boehringer Ingelheim), Anat Loewenstein (Israel)
5'

Paolo Gasparini

Italy

Title tbd

 
5'
Marion Munk
Switzerland
BRIDGE Group perspective
 
5'
TBD
CAM Group perspective
 
5'
Frank Holz
Germany
Title tbd
 
5'
Jeffrey Heier
USA
Subretinal transplantation of human stem cell-derived RPE (ASP7317) for the treatment of advanced GA
 
5'
Quan Dong Nguyen
USA
Subretinal CTx001 for Geographic Atrophy
 
5'
Daniel Ting
USA
The role of AI in evaluating GA
 
5'
Peter Francis
Ray Therapeutics
RTx-021 treatment of Geographic Atrophy and Stargardt Disease
 
20'
Discussion
 
 

Friday, 4 December 2026

07:45 – 08:15
Networking Breakfast
08:15 – 09:45

DOLPHIN TANK @EYENOVATE | FLORetina-ICOOR 2026

Where visionary ideas meet strategic capital

Review Committee: Emmett Cunningham, Francesco Faraldi, Len Feiner, John Pollack, Paola Pozzi, Firas Rahal,  Cynthia Toth, Monica Volpin

Length
Speaker
Talk
Note
20'
 
Keynote Lectures
 
Presentations by selected “Rising Stars”
4'
Kenichiro Kuninobu
Feliqs Corporation
Two frontiers, one vision: advancing novel therapies for ROP and pterygium
 
 
TBD
 
 
Competition: presentations by selected “Innovators”
 
TBD
Award: Best Innovation Presentation
 
 
TBD
Dolphin Tank Innovation Award
 

Join us for a unique, multidisciplinary forum with leading industry, investor, and clinical care innovators.

Register Now
Need Accomodations at FLORetina?